Refine by
Locations
- Europe
- Albania
- Andorra
- Austria
- Belarus
- Belgium
- Bosnia & Herzegovina
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Faroe Islands
- Finland
- France
- Germany
- Greece
- Hungary
- Iceland
- Ireland
- Italy
- Kosovo
- Latvia
- Liechtenstein
- Lithuania
- Luxembourg
- Macedonia
- Malta
- Moldova
- Monaco
- Montenegro
- Netherlands
- Northern Ireland
- Norway
- Poland
- Portugal
- Romania
- San Marino
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Turkey
- Ukraine
- United Kingdom
- Vatican City
Disease Progression Suppliers In Europe
8 companies found
Technologybased inKirkland, WASHINGTON (USA)
Heart failure is a progressive disease. It’s an expensive disease. It’s a devastating disease. Over 20% of heart failure patients with FMR die within the first year of diagnosis and 50% die within five years.1 Each year thousands of these patients ...
Technologybased inBubendorf, SWITZERLAND
CIS Pharma is an innovator in the life science industry in the field of Oncology and Ophthalmolog. We were awarded with the European Frost & Sullivan Technology Innovation Award for our unique smart polymer technologyœ, says Christoph Schäfer, CEO ...
Technologybased inParis, FRANCE
Pixium Vision, created in December 2011, is a bioelectronics and brain machine interface technology company specialized in neuromodulation application whose mission is to create a world of bionic vision for those who have lost their sight, enabling ...
Age-related macular degeneration is the leading cause of severe vision loss and legal blindness in people over the age of 65 in North America and Europe. The global impact is significant with current projected estimates for people living with AMD of ...
Technologybased inEttlingen, GERMANY
We are a pioneering medical device company focused on transforming the lives of patients with difficult to treat cancers by applying our discoveries in bioelectromagnetics to targeted treatment of cancer. Our patient-based research using low and ...
The TheraBionic P1 produces low levels radiofrequency (RF) electromagnetic fields, which are amplitude-modulated at tumor-specific frequencies. The device is coupled with a spoon-shaped antenna, which is placed in the patient’s mouth, more ...
Technologybased inCopenhagen V, DENMARK
Founded in 1999 in Copenhagen, Denmark, we are a dual-listed, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. We are led by an experienced ...
Tisotumab Vedotin is an antibody-drug conjugate (ADC) targeted to tissue factor (TF), a protein involved in tumor signaling and angiogenesis.1 It is composed of Genmab’s human monoclonal antibody (mAb) that binds to TF and Seagen’s ADC ...
Technologybased inKiel, GERMANY
tiakis biotech AG (“tiakis”) – formerly Proteo Biotech AG - is the next generation preventive therapeutic technology company. We focus on our clinical-stage proprietary and pioneering tissue protective drug ...
Tiprelestat is a pioneering anti-inflammatory and tissue protective drug being developed for the treatment of pulmonary-arterial hypertension, the prevention of serious disease progression of COVID-19 and the ...
Technologybased inRegensburg, GERMANY
numares is an innovative diagnostics company. We focus on the discovery, development and commercialization of diagnostic tests, using metabolite constellations to solve unmet medical needs that could not be addressed by single biomarker-based ...
Common cancers with established benefit of early diagnosis but for which there are no sensitive or specific tests are prostate, bladder and liver cancer1. Expensive imaging procedures are routinely required in clinical practice for diagnosis or to ...
Technologybased inOxford, UNITED KINGDOM
Oxford Brain Diagnostics Ltd is rethinking how brain health is assessed and managed. Founded in neuropathological and neuroimaging expertise, the company’s patented Cortical Disarray Measurement (CDM) technology uses MRI brain scan data to support ...
We can provide longitudinal patient results based on changes across baseline and time points in accordance with your clinical trial protocol. Grey matter quality changes can also be provided in brain visualisations over multiple time periods. We can ...
